<

BIOPHYTIS (EPA:ALBPS) - Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)

Transparency directive : regulatory news

08/04/2024 23:10



Other stories

30/04/2024 02:21
30/04/2024 03:31
30/04/2024 03:04
30/04/2024 01:01
29/04/2024 16:26
29/04/2024 19:03
29/04/2024 14:04
29/04/2024 16:08
29/04/2024 22:03
29/04/2024 16:01
29/04/2024 23:01
30/04/2024 03:01
29/04/2024 16:25
30/04/2024 00:24
29/04/2024 21:31
29/04/2024 18:39
29/04/2024 22:03
29/04/2024 19:52
29/04/2024 12:07
29/04/2024 21:26
29/04/2024 12:26
29/04/2024 18:58
29/04/2024 23:42
29/04/2024 17:14
30/04/2024 00:41
30/04/2024 01:28
29/04/2024 22:14
29/04/2024 21:31
29/04/2024 23:06
29/04/2024 22:16
29/04/2024 12:36
29/04/2024 13:30
28/04/2024 19:21
29/04/2024 22:10
29/04/2024 18:25
29/04/2024 21:01
28/04/2024 12:18
30/04/2024 00:30